home / stock / goss / goss message board
Subject | By | Source | When |
---|---|---|---|
Agreed! | Dutch4 | investorshub | 03/24/2023 5:03:33 PM |
Institutionals shorting this unmercilessly. Three trades totalling | hippityhop | investorshub | 12/22/2022 9:20:39 PM |
This is a 100/200 percenter in next 3 | hippityhop | investorshub | 12/19/2022 4:53:28 PM |
Raymond James Initiates Coverage On Gossamer Bio with | crudeoil24 | investorshub | 04/20/2022 11:43:11 PM |
Gossamer Bio, Inc. is a clinical-stage biopharmaceutical company. | crudeoil24 | investorshub | 04/20/2022 11:41:45 PM |
News, Short Squeeze, Breakout and More Instantly...
Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), will present up...
- Transformative Development and Co-Commercialization Collaboration with Chiesi - - Ongoing PROSERA Phase 3 Study in PAH Expected to Readout in Q4 2025 - - Registrational Phase 3 in PH-ILD Expected to Commence in Mid-2025 - - TORREY Phase 2 PAH Results Published in Lancet ...
Gossamer Bio Inc (NASDAQ:GOSS) and Italy-based Chiesi Farmaceutici S.p.A, have entered a global collaboration and license agreement ...